Patents Represented by Attorney, Agent or Law Firm William R. Boudreaux
-
Patent number: 7335799Abstract: The present invention relates to novel hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, pancreatitius, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, metabolic syndrome disorders (e.g., Syndrome X), thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: GrantFiled: December 23, 2003Date of Patent: February 26, 2008Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 7192940Abstract: The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.Type: GrantFiled: July 16, 2004Date of Patent: March 20, 2007Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 7119221Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.Type: GrantFiled: December 23, 2003Date of Patent: October 10, 2006Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis Henri Dasseux, Carmen Daniela Oniciu
-
Patent number: 7015232Abstract: The present invention is directed to ACE inhibitor-containing compositions stabilized by the presence of magnesium oxide. Preferably, the ACE inhibitor, quinapril, is protected from certain forms of degradation when prepared in a pharmaceutical composition consisting essentially of magnesium oxide as the stabilizing agent. The presence of magnesium oxide also lends itself to favorable processing conditions during the manufacture of ACE inhibitor-containing compositions, especially processing by wet granulation.Type: GrantFiled: April 22, 2002Date of Patent: March 21, 2006Assignee: Warner-Lambert Company, LLCInventors: Jane Ellen Daniel, Michael Ray Harris, Gerard Clifford Hokanson, Jay Weiss
-
Patent number: 6828331Abstract: What is disclosed are growth hormone secretagogues, and their uses, of the formula wherein R1 is C6H5CH2OCH2—, C6H5 (CH2)3— or indol-3-ylmethyl; Y is pyrrolidin-1-yl, 4-C1-C6 alkylpiperidin-1-yl or NR2R2; R2 are each independently a C1 to C6 alkyl; R3 is 2-napthyl or phenyl para-substituted by W; W is H, F, CF3, C1-C6 alkoxy or phenyl; and R4 is H or CH3, or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: July 25, 2001Date of Patent: December 7, 2004Assignee: Eli Lilly and CompanyInventors: Jeffrey Alan Dodge, Charles Willis Lugar, III
-
Patent number: 6723739Abstract: A compound of the formula or a pharmaceutically acceptable salt or solvate thereof. Also provided by the invention are methods of use of the above compounds, and processes for the preparation thereof.Type: GrantFiled: March 15, 1995Date of Patent: April 20, 2004Assignee: Eli Lilly and CompanyInventors: Jeffrey A. Dodge, Charles A. Frolik, Terry D. Lindstrom, Charles W. Lugar, III
-
Patent number: 6639076Abstract: This invention relates to novel compounds of formula I wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.Type: GrantFiled: April 17, 2001Date of Patent: October 28, 2003Assignee: Eli Lilly and CompanyInventors: Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
-
Patent number: 6562862Abstract: A method of inhibiting a physiological disorder associated with an excess of neuropeptide Y or its symptoms comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, or wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: October 20, 1994Date of Patent: May 13, 2003Assignee: Eli Lilly and CompanyInventors: Robert F. Bruns, Jr., Donald R. Gehlert, J. Jeffry Howbert, William H. W. Lunn
-
Patent number: 6545027Abstract: A method of modulating NF-kB transcription factor comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: June 7, 1995Date of Patent: April 8, 2003Assignee: Eli Lilly and CompanyInventors: David T. Berg, David S. Calnek, Brian W. Grinnell
-
Patent number: 6489355Abstract: This invention encompasses methods for the inhibition of a physiological disorder associated with amyloidogenic proteins, which method comprises administering to a human in need thereof an effective amount of a compound of Formula I wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamthylenemino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: December 1, 1993Date of Patent: December 3, 2002Assignee: Eli Lilly and CompanyInventor: William H. W. Lunn
-
Patent number: 6436958Abstract: A method of inhibiting auto immune diseases comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, —CH3, or wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: May 19, 1995Date of Patent: August 20, 2002Assignee: Eli Lilly and CompanyInventor: Steven H. Zuckerman
-
Patent number: 6417198Abstract: A method of inhibiting one or more CNS disorders in a post-menopausal woman comprising administering to a female human in need of treatment an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: December 21, 1993Date of Patent: July 9, 2002Assignee: Eli Lilly and CompanyInventors: Henry U. Bryant, Andrew L. Glasebrook, Timothy A. Grese, David L. Phillips
-
Patent number: 6403615Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I:Type: GrantFiled: September 29, 2000Date of Patent: June 11, 2002Assignee: Eli Lilly and CompanyInventor: George Joseph Cullinan
-
Patent number: 6395769Abstract: This invention provides methods which are useful for the inhibition of the various medical conditions associated with estrogen deprivation syndrome including osteoporosis and hyperlipidemia utilizing compounds of formula I:Type: GrantFiled: May 12, 2000Date of Patent: May 28, 2002Assignee: Eli Lilly and CompanyInventor: George Joseph Cullinan
-
Patent number: 6395719Abstract: The present invention is directed to increasing levels of acetylcholine by the administration of 2-aryl-3-aroylbenzo[b]thiophenes.Type: GrantFiled: November 14, 2000Date of Patent: May 28, 2002Assignee: Eli Lilly and CompanyInventors: Henry Uhlman Bryant, Michele Annette Glinn, Steven Marc Paul, Xin Wu
-
Patent number: 6353003Abstract: The current invention relates to a method for decreasing levels of homocysteine and/or C-reactive protein in humans comprising administering to a mammal in need thereof an effective amount of a compound of formula I: or a pharmaceutical salt or solvate thereof.Type: GrantFiled: May 3, 1999Date of Patent: March 5, 2002Assignee: Eli Lilly and CompanyInventor: Pamela Wang Anderson
-
Patent number: 6329342Abstract: The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.Type: GrantFiled: February 18, 2000Date of Patent: December 11, 2001Assignee: Eli Lilly and CompanyInventors: Raymond F. Kauffman, Alan D. Palkowitz
-
Patent number: 6303634Abstract: A method of preventing breast cancer comprising administering for a sufficient term to a human in need thereof an effective amount of a compound having the formula and pharmaceutically acceptable salts and solvates thereof.Type: GrantFiled: August 5, 1999Date of Patent: October 16, 2001Assignee: Eli Lilly and CompanyInventors: Fredric J Cohen, Robert S Eckert, Joan E Glusman, Ronald K Knickerbocker, Nikolaus T Nickelsen, Teri J Scott
-
Patent number: 6288108Abstract: The current invention relates to a method for increasing levels of acetylcholine comprising administering to a mammal in need thereof, an effective amount of a compound of formula (I), and optionally an AChE inhibitor.Type: GrantFiled: November 14, 2000Date of Patent: September 11, 2001Assignee: Eli Lilly and CompanyInventors: Henry Uhlman Bryant, Michele Annette Glinn, Steven Marc Paul, Xin Wu
-
Patent number: 6274601Abstract: A method of inhibiting ulcerative mucositis comprising administering to a human in need thereof an effective amount of a compound having the formula wherein R1 and R3 are independently hydrogen, wherein Ar is optionally substituted phenyl; R2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.Type: GrantFiled: September 22, 1995Date of Patent: August 14, 2001Assignee: Eli Lilly and CompanyInventor: George J. Cullinan